Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.49 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 6/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | RNF4 | P78317 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1259999 | 0.88 | KDR (0.57) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL1259886 | 0.88 | KDR (0.49) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL12892680 | 0.80 | KDR (0.50) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL1259495 | 0.80 | RNF4 (0.46) | RNF4HTTALDH1A1 | |
| SCHEMBL14949677 | 0.79 | KDR (0.58) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL1258121 | 0.78 | KDR (0.55) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL4289198 | 0.78 | KDR (0.62) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL1259926 | 0.78 | RAB9A (0.51) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL1258102 | 0.78 | KDR (0.46) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL1258100 | 0.76 | KDR (0.53) | KDRFLT1AURKAPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | KDR 966/4885FLT1 1499/4885AURKA 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.